Investor's Business Daily |
Novo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial
Investor's Business Daily Novo Nordisk (NVO) stock popped Tuesday after AstraZeneca (AZN) said its type 2 diabetes drug didn't reduce the risk of cardiovascular events in a trial, leaving Eli Lilly (LLY) to break the tie in 2019. In midday trading on the stock market today ... |
![[OC] Build Your Own Dexcom App update- base version updates](https://4.bp.blogspot.com/-O3EpVMWcoKw/WxY6-6I4--I/AAAAAAAAB2s/KzC0FqUQtkMdw7VzT6oOR_8vbZO6EJc-ACK4BGAYYCw/w680/nth.png)
Social Plugin